quinoxalines has been researched along with cresyl violet in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baubichon, D; Blanchet, G; Carpentier, P; Delamanche, IS; Denoyer, M; Lallement, G; Pernot-Marino, I | 1 |
| Barth, A; Malouf, AT; Newell, DW; Ricciardi, TN | 1 |
| Alcala, SR; Danylkova, NO; McLoon, LK; Pomeranz, HD | 1 |
3 other study(ies) available for quinoxalines and cresyl violet
| Article | Year |
|---|---|
Neuroprotective activity of glutamate receptor antagonists against soman-induced hippocampal damage: quantification with an omega 3 site ligand.
Topics: Animals; Autoradiography; Benzoxazines; Brain; Brain Diseases; Excitatory Amino Acid Antagonists; Hippocampus; Isoquinolines; Ligands; Male; Oxazines; Phencyclidine; Quinoxalines; Rats; Rats, Wistar; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate; Seizures; Soman | 1993 |
Glycine causes increased excitability and neurotoxicity by activation of NMDA receptors in the hippocampus.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Animals, Newborn; Benzoxazines; Cell Death; Dizocilpine Maleate; Electrophysiology; Excitatory Amino Acid Antagonists; Glycine; Hippocampus; Neurons; Neurotoxins; Organ Culture Techniques; Oxazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 1997 |
Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy.
Topics: Adrenergic alpha-Agonists; Animals; Axons; Benzoxazines; Brimonidine Tartrate; Cell Survival; Coloring Agents; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Neuroprotective Agents; Ophthalmic Solutions; Optic Neuropathy, Ischemic; Oxazines; Quinoxalines; Rats; Rats, Long-Evans; Retinal Ganglion Cells | 2007 |